Medical Affairs Information Hub
At OPKO Health, we are dedicated to advancing the understanding of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD).
We have gathered information and research to help healthcare professionals improve the management of SHPT in CKD using extended-release calcifediol (ERC).
SHPT and CKD
More than 35.5 million people in the US are living with CKD, and SHPT is a common complication, occurring in approximately half of patients with CKD worldwide.1-3 Get to know the complex underpinnings of SHPT and the impact it may have on patients as the disease progresses.
Examine the scienceResearch Advances
Our resource library includes research publications and medical education materials to help healthcare professionals broaden their understanding of SHPT, its impact, and available therapies.
Access resources
REFERENCES: 1. Centers for Disease Control and Prevention (CDC). Chronic Kidney Disease in the United States, 2023. US Department of Health and Human Services, CDC; 2023. 2. Levin A, Bakris GL, Molitch M, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int. 2007;71(1):31-38. doi:10.1038/sj.ki.5002009 3. Wang Y, Liu J, Fang Y, Zhou S, Liu X, Li Z. Estimating the global prevalence of secondary hyperparathyroidism in patients with chronic kidney disease. Front Endocrinol (Lausanne). 22024;15:1400891. doi:10.3389/fendo.2024.1400891
Have questions or need more information?
Contact Medical Affairs